Omnicell (OMCL) has been on investors’ radar after recent trading left the shares with a one-month return of about a 9% decline and a past three-month move of roughly a 30% decline.

At a share price of US$35.47, Omnicell’s 7 day share price return of 3.9% contrasts with a 30 day share price return of about a 9% decline and a year to date share price return of about a 21% decline. The 1 year total shareholder return of 14.1% shows the effect of holding through recent swings.

If you are weighing Omnicell’s recent volatility and want to broaden your search, this could be a good moment to see what else stands out in healthcare technology, including 36 healthcare AI stocks.

With Omnicell trading at US$35.47, sitting at a discount to both some estimates of intrinsic value and the average analyst target, the key question is whether this is a genuine entry point or whether the market already reflects expectations for future growth.

Most Popular Narrative: 38.2% Undervalued

Omnicell’s fair value in the most followed narrative sits at US$57.43 per share, well above the last close of US$35.47, which puts a lot of focus on the assumptions behind that gap.

The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.

Curious what kind of revenue mix shift and profit profile would need to back up that valuation gap? The narrative leans heavily on recurring software scale and richer margins. The details sit in a tight set of growth, margin, and earnings assumptions that you will want to see in full.

Result: Fair Value of $57.43 (UNDERVALUED)

However, this depends on hospital cabinet replacements and OmniSphere adoption not being delayed by tariff costs or slower capital budgets, which could quickly challenge that upside story.

Next Steps

With that mix of concern and optimism around Omnicell, this is a good time to look at the numbers yourself and stress test the narratives before they move on without you, starting with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Omnicell has caught your attention, do not stop here. Use this moment to scan the wider market and line up your next set of potential opportunities.

• Target resilient candidates that prioritise strength over excitement by checking out 73 resilient stocks with low risk scores as a starting list for your watchlist.
• Hunt for potential mispricings across the market by reviewing 62 high quality undervalued stocks and see which names stand out against your own criteria.
• Spot companies that many investors might be overlooking but with solid underpinnings by screening through screener containing 24 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.